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I. INTRODUCTION AND SUMMARY
Biotechnological I breakthroughs are expected to improve greatly
our quality of life, by providing cures to diseases, enhancing the quan-
tity and nutrition of food, and offering non-chemical alternatives to pol-
lution remediation. Not surprisingly, industry proponents tout biotech-
nology as the panacea for many basic human problems.'
More cautious observers of the industry, however, assert that eIvgi-
1. Biotechnology has been defined as "[t]he application of organisms, biological
systems or biological processes to manufacturing and service industries. This definition
has been extended to include any process in which organisms, tissues, cells, organelles
or isolated enzymes are used to convert biological or other raw materials to products..
* ." J. COOMBS, DICTIONARY OF BIOTECHNOLOGY 41 (1986).
2. See, e.g., ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT,
BIOTECHNOLOGY: ECONOMIC AND WIDER IMPACTS 22 (1989).
(255)
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neering novel organisms could create unanticipated hazards.' Those
who are wary of lax regulation of biotechnology products note that
while knowledge about scientific mechanisms is incomplete, research
continues at a breakneck pace.' They fear that incomplete assessment
of genetically modified organisms could have unforeseen, even disas-
trous consequences once the organisms or their products reach the con-
suming public.'
Biotechnology has received increased attention by health and
safety regulators in recent years. Whereas the trend in the United
States has been to ease the regulatory burden,6 the emphasis in the
European Community (E.C.)7 has been to tighten and harmonize regu-
3. See, e.g., MARGARET MELLON, NAT'L WILDLIFE FED'N, BIOTECHNOLOGY AND
THE ENVIRONMENT 13 (1988) (discussing our inability to predict the effects that re-
leases of genetically modified organisms may have on complex ecological systems).
4. See, e.g., id. at 8-9 ("Our understanding about ecological processes simply lags
behind our knowledge of molecular processes. And we have almost no practical experi-
ence with engineered organisms that have been released into nature.").
5. See, e.g., id. at 31-32. For example, Rolling Stone magazine writer Tom Curtis
suggests that AIDS may have been transmitted to humans through a polio vaccine that
had been cultured in monkey cells containing the HIV virus. Tom Curtis, The Origin
of AIDS, ROLLING STONE, Mar. 19, 1992, at 54, 54. Curtis speculates that the respon-
sible vaccine may have been one that was widely distributed between 1957 and 1960
during a polio immunization campaign in Zaire. Id. at 56. Although many have dis-
missed this story as sensationalist journalism, see Carol Saline, Did Hilary Koprowski
Unleash AIDS?, PHILADELPHIA MAG., May 1992, at 73, 114, the virus was first de-
tected in a human in 1959 in Zaire, Curtis, supra at 56, and the controversy persists.
Saline, supra at 114.
Some fear that this sort of mingling of organic materials among species can pro-
duce wholly unanticipated results, such as the transmission of a strain of virus that is
innocuous in one species but pathogenic in another, or the transmission of an innocuous
strain that mutates into a virulent form. For example, the monkey B virus produces a
very mild reactiohi in monkeys, but can paralyze and kill humans. Curtis, supra at 57.
Because the risks of this virus were known, monkeys were generally tested for it, and
most polio vaccines were not contaminated with the monkey B virus. Id.
6. See, e.g., FDA Head of Biologics Will Accelerate Review Timetable, BIOTECH-
NOLOGY NEWSWATCH, Mar. 16, 1992, at 1, 1 (1992).
7. The European Community was established when the Treaty of Rome came into
force on January 1, 1958. TREATY ESTABLISHING THE EUROPEAN COMMUNITY [EEC
TREATY]. This Treaty, together with the Treaty of Paris (April 1951), TREATY ESTAB-
LISHING THE EUROPEAN COAL AND STEEL COMMUNITY [ECSC TREATY], and a second
Treaty of Rome (March 1957), TREATY ESTABLISHING THE EUROPEAN ATOMIC EN-
ERGY COMMUNITY [EURATOM TREATY], formed the Constitution of the European
Community. The goal of the Treaty of Rome was to integrate the European market in
terms of goods, persons, services and capital. See EEC TREATY arts. 2-3 & 8A. Nearly
ten years later, on July 1, 1967, the separate councils and commissions of these Com-
munities fused into one. See generally EUROPE 1992: AN AMERICAN PERSPECTIVE 1,
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latory standards.8
One recently proposed regulation in the European Community
that concerns marketing authorizations for biotechnology-derived ne-
dicinal products is particularly noteworthy.9 The proposal has been
wending its way through the Community's cooperation procedure10
app.1-I at 51-52 (Gary C. Hufbauer ed., 1990).
8. See, e.g., AUDREY WINTER ET AL., BUREAU OF NAT'L AFFAIRS, EUROPE WITH-
OUT FRONTIERS: A LAWYER'S GUIDE 272-77 (1989).
9. Amended Commission Proposal for a Council Regulation (EEC) Laying Down
Community Provisions for the Authorization and Supervision of Medicinal Products for
Human and Veterinary Use and Establishing a European Agency for the Evaluation of
Medicinal Products, 1991 O.J. (C 310) 7 [hereinafter Amended Proposed Regulation].
The regulation will establish a binding, centralized marketing authorization sys-
tem for biotechnology-derived pharmaceuticals. Commission Proposal for a Council
Regulation (EEC) Laying Down Community Procedures for the Authorization and Su-
pervision of Medicinal Products for Human and Veterinary Use and Establishing a
European Agency for the Evaluation of Medicinal Products, 1990 O.J. (C 330) 1, 1
(First recital) [hereinafter Proposed Regulation]. Marketing authorizations will be
granted only where a scientific evaluation indicates the product meets quality, safety
and efficacy standards. Id. (Fourth recital). Although the current system does provide
for central review, decisions by the reviewing committee are nonbinding. See id. (Sec-
ond recital). Thus companies wishing to market in the Community must still obtain
marketing approval from individual Member States. In contrast, the proposed regula-
tion will permit Community-wide marketing for authorized pharmaceuticals. See Min-
isters Set to Approve Central Medicines Agency, 1 WORLD PHARMACEUTICALS REP.,
July 20, 1992, at 3, 3-4, for a discussion of the proposal.
10. Proposed legislation is reviewed and revised by various institutions within the
E.C. Legislation generally takes the form of a directive (which is only fully imple-
mented through national legislation by each Member State), or a regulation (which is
binding on all Member States and does not require national legislation for
implementation).
Under the cooperation procedure, the Commission proposes legislation. The Com-
mission is composed of 17 members; all 12 E.C. countries have at least one Commis-
sioner. Following the Commission proposal, the Parliament reads the proposed legisla-
tion and issues an advisory opinion. The Parliament is composed of 518 members who
are elected directly in each E.C. country. The Council of Ministers then votes on the
proposal. Each Member State is represented by a Minister, though Minister votes are
weighted according to population and Gross Domestic Product. Unlike participants on
most other bodies in the E.C., the Ministers are expected to represent the interests of
their Member States, rather than the Community. The Council submits the legislation
to the Parliament, which conducts a second reading. If Parliament approves the legisla-
tion, it is adopted; if Parliament rejects the legislation, it is sent to the Council of
Ministers for a vote. If Parliament amends the legislation, it is submitted to the Com-
mission to redraft and re-propose to the Council, whereupon the Council will vote. In
addition to these standardized procedures, the Economic and Social Committee may
also submit an advisory opinion to the Commission. See INT'L Div., U.S. CHAMBER OF
COMMERCE, EUROPE 1992: A PRACTICAL GUIDE FOR AMERICAN BUSINESS 18-24
(1989) for a succinct overview of the E.C. legislative procedure.
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since 1990, and appears to be nearing official adoption.11 The most sali-
ent element of the proposal is centralization of review, 12 based on spe-
cific public health criteria of quality, safety and efficacy.' 3 Although it
harmonizes Community health standards, this regulation also facili-
tates the free movement of these biotechnology-derived products
throughout the E.C." Nonetheless, health issues dominate the proposed
regulation, as evidenced by a statement from its preamble:
[I]n the interests of public health and the consumers of medici-
nal products it is necessary that decisions on the authorization
of such medicinal products should be based on the objective sci-
entific criteria of the quality, the safety and the efficacy of the
medicinal product concerned to the exclusion of economic or
other considerations . . . .
Industry response in Europe to this proposed regulation has been
cautiously optimistic. 6 Most Community biotechnology organizations
and firms seem to believe that harmonization and centralization will
improve their ability to market pharmaceuticals once approval is ob-
tained, but they also fear that procuring authorization may result in
"administrative juggernaut."' 7
U.S. industries' reaction to the E.C. regulations is less clear. On
the one hand, the E.C. proposal will impose regulatory requirements on
11. The proposed regulation has been drafted and submitted by the Commission,
Proposed Regulation, supra note 9; reviewed by the Economic and Social Committee,
Economic and Social Committee Opinion, 1991 O.J. (C 269) 84; commented upon by
the Parliament, Parliament Amended Text, 1991 O.J. (C 183) 145; amended by the
Commission, Amended Proposed Regulation, supra note 9, at 7; and submitted to the
Council of Ministers for a vole. The Council is expected to render its decision before
the end of 1992. See, e.g., EC: Europe Documents; No 1796 - State of Completion of
the Single Market (3 of 3), Reuter Textline, Agence Europe, Sept. 11, 1992, T 86,
available in LEXIS, Nexis Library.
12. Proposed Regulation, supra note 9, at I (Third recital).
13. Amended Proposed Regulation, supra note 9, at 1 (Fourth recital).
14. Proposed Regulation, supra note 9, at 1 (First recital). The European Com-
munity is currently composed of twelve members: France, Germany, Italy, the United
Kingdom, Spain, the Netherlands, Belgium, Greece, Portugal, Denmark, Ireland, and
Luxembourg.
15. Amended Proposed Regulation, supra note 9, at 1 (Fourth recital).
16. See, e.g., Elisabeth Tacey, Pharmaceuticals: The Route to the Market, FIN.
TIMES, Nov. 21, 1990, at 39.
17. See id. The "administrative juggernaut" term originated with an E.C. Com-
mission official, who claimed the harmonized procedure would not lead to this result.
Ministers Set to Approve Central Medicines Agency, supra note 9, at 3.
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companies that market in the Community. On the other hand, however,
companies that meet those standards will gain access to twelve national
markets. Thus, these proposed regulations will profoundly improve the
ability of international pharmaceutical companies to reach European
consumers.
The E.C. proposal contrasts significantly with federal Food and
Drug Administration (F.D.A.) laws, regulations and policies. Federal
statutes governing pharmaceuticals in the U.S. 18 have not been
amended with new provisions addressing biotechnology-derived prod-
ucts. 9 Instead, the F.D.A. generates guidance documents to apprise
applicants of recommended procedures.2 0 Although the agency updates
these documents to keep current with technology and agency concerns,
the constantly evolving character of F.D.A. review opens the agency to
external pressures, particularly from the White House. Partly pursuant
to such Executive Branch influence,21 the F.D.A. recently promised to
simplify and accelerate approval of these products.2 2 In essence, ap-
proval by the F.D.A. is less predictable and consistent than will be the
case in the European Community.
Some U.S. officials and industry representatives have become in-
creasingly critical of burdensome federal health standards, particularly
as the biotechnology industry has become more competitive.2 3 Although
the U.S. leads globally in this technology, its competitive edge is not
assured .2 Consequently, industry proponents have stepped up their ef-
18. Federal Food, Drug and Cosmetic Act (FFDCA), 21 U.S.C. §§ 301-392
(1988); Public Health Service Act, 42 U.S.C. §§ 262-263n (1988).
19. Food and Drug Administration: Statement of Policy for Regulating Biotech-
nology Products, 51 Fed. Reg. 23,309, 23,310 (1986).
20. Id. at 23,311. *
21. See, e.g., Philip J. Hilts, U.S. Says It Will Speed Gene-Product Approvals,
N.Y. TIMES, Mar. 6, 1992, at D2. [hereinafter U.S. Says It Will Speed]; see also Vice
President Dan Quayle, Remarks to the Food and Drug Law Institute Conference re:
President's Council on Competitiveness (Dec. 11, 1991), in Federal News Service, Dec.
11, 1991, available in LEXIS, Nexis Library.
22. See, e.g., FDA Head of Biologics Will Accelerate Review Timetable, supra
note 6, at 1.
23. See, e.g., U.S. Patent Decisions, Federal Regs Loom Largefor Biotech Firms,
INDUS. BIOPROCESSING, June 1991, at 2, 2.
24. See, e.g., OFFICE OF TECHNOLOGY ASSESSMENT, BIOTECHNOLOGY IN A
GLOBAL ECONOMY 19-21 (1991) (noting the U.S.' general preeminence in the technol-
ogy, but also Japan's strength in fermentation processes and Europe's strength in
pharmaceuticals and agriculture); THE PRESIDENT'S COUNCIL ON COMPETITIVENESS,
REPORT ON NATIONAL BIOTECHNOLOGY POLICY 5 (1991) (asserting that Japan and
Europe have begun to challenge the U.S.' lead in the industry).
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forts to ease the regulatory burden."'
Despite the F.D.A.'s recent measures to streamline the biotechnol-
ogy approval process, adoption of the proposed E.C. regulation will
force U.S. drug companies marketing in Europe to meet the more
clearly defined Community safety and efficacy standards.26 Because of
keen competition in this industry, U.S, companies hoping to maintain
their current strength must elect to meet stringent E.C. public health
and scientific criteria. Their ability to reach European markets will re-
quire it. Additionally, because all countries (including biotechnology
strongholds Japan and Switzerland) will also experience pressure to
comply with these comprehensive standards, no country will endure an
unfair disadvantage. The worldwide effect of this E.C. Commission
proposal will be improved health and safety for the public, as well as
increased access to important markets for the biotechnology industry.
This Note explores the far-reaching impact of this proposal, par-
ticularly with reference to the United States. Section II examines sev-
25. For example, the industry has been involved actively with President Bush's
Council on Competitiveness and its anti-regulatory agenda. The Council strives to
maintain and improve U.S. competitiveness by developing human resources, promoting
technological progress, removing "barriers to innovation," assessing "governmentally-
imposed burdens on the free enterprise system," and removing "domestic barriers to
the flow of goods and services." THE PRESIDENT'S COUNCIL ON COMPETITIVENESS,
supra note 24, at 25. The association between industry and the Council is so close, in
fact, that House Energy and Commerce/Health Committee Chair Waxman (D-Calif.)
has begun to investigate alleged improper ties between Eli Lilly and Company and the
Council. See Rep. Waxman Investigating Quayle Council Proposals for FDA Drug
Approvals; Possible Hearing Angles are Lilly Influence and Intra-Agency Reserva-
tions, 53 F-D-C REP. 15-16 (1991). Evidence of Lilly's extensive ties to the Council
include President Bush's former membership on Lilly's board of directors, Vice Presi-
dent Quayle's prior representation as a senator of this Indiana constituent, Lilly Vice
President Mitchell Daniel's political directorship in Reagan's administration, and
Lilly's technical assistance with Council on Competitiveness proposals. Id.
In addition, trade groups such as the Industrial Biotechnology Association ac-
knowledge that the Council has requested their help in preventing Congress from cut-
ting the Council's funding. See Bush to Biotechs: Save COC from Congress, BIOTECH-
NOLOGY NEWSWATCH, Sept. 7, 1992, at 12 (1992). Senator John Glenn (D-Ohio) has
threatened to take measures to eliminate the Council's funding, alleging "[T]he council
carries out its agenda under a shroud of secrecy-a shroud that is only lifted to grant
access to certain special interests." Id.
26. Before U.S. products can be marketed in the E.C. they must receive-market-
ing authorization pursuant to Article 3 from the Proposed Regulation. ("No medicinal
product which is [developed by a biotechnological process] shall be placed on the mar-
ket within the Community unless authorization has been granted by the Community in
accordance with the priovisions of this Regulation." Proposed Regulation, supra note 9,
art. 3, at 3.)
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eral key elements of the proposed regulation, following a brief look at
previous Community regulations. Section III discusses industry's re-
sponse to the proposal, both in Europe and the United States. Section
IV contrasts the E.C. proposal with current U.S. laws and policies. Fi-
nally, Section V concludes that this proposal will have what many con-
sider an almost inconceivable effect: benefits for both public welfare
and American industry.
II. THE EUROPEAN COMMUNITY PROPOSED REGULATION
AUTHORIZING MARKETING OF BIOTECHNOLOGY DRUGS
Beginning in 1975, the European Community operated under a
marketing system in which individual Member States were responsible
for upholding Community standards of safety, quality and efficacy.
27
Member States granted marketing authorizations, though States could
consult the E.C. Committee for Proprietary Medicinal Products
(CPMP) for non-binding opinions about authorization refusals, author-
ization suspensions or non-compliance with authorizations. 8
The CPMP review procedures were modified in Council Directive
87/22 eleven years later for several reasons, including the following:
1) the provisions "[we]re not sufficient to open up to high-tech-
nology medicinal products the large Community-wide single
market they require, '"29
2) "the scientific expertise available to each of the national au-
thorities [wa]s not always sufficient to resolve problems posed
by high-technology medicinal products," 30
3) it was necessary to unify Community decisionmaking by
"provid[ing] for a Community mechanism for concertation,
prior to any national decision relating to a high-technology me-
27. Second Council Directive 75/319 on the Approximation of Provisions Laid
Down by Law, Regulation or Administration Action Relating to Proprietary Medicinal
Products, art. 4, 1975 O.J. (L 147) 13, 14, amended by Council Directive 83/570,
1983 O.J. (L 332) 1, 9, last amended by Council Directive 89/381, 1989 O.J. (L 181)
44, 45. Article 4 standards in Directive 75/319 are those enumerated in Council Direc-
tive 65/65 on the Approximation of Provisions Laid -Down by Law, Regulation or Ad-
ninistration Action Relating to Proprietary Medicinal Products, 1965 O.J. (L 22) 369.
28. Second Council Directive 75/319, art. 8(2), 1975 O.J. (L 147) 13, 15; see
also supra note 9.
29. Council Directive 87/22 on the Approximation of National Measures Relating
to the Placing on the Market of High-Technology Medicinal Products, Particularly
Those Derived from Biotechnology, 1987 O.J. (L 15) 38, 38 (Fifth recital).
30. Id. (Sixth recital).
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dicinal product,"'" and
4) there was a "need for the adoption of new technical rules
applying to high-technology medicinal products ... so as not to
endanger the advance of pharmaceutical research whilst at the
same time ensuring optimum protection of public health within
the Community. 32
In essence, the new Directive 87/22 required Member States to refer
biotechnology marketing applications to the CPMP for an opinion
before the State could award a marketing authorization. 33 Although
Committee review became mandatory under this Directive, Member
States were still entitled to reach their own decisions, and merely noti-
fied the Committee of their ultimate conclusions.34
Dissatisfaction with Directive 87/22 led to the most recent regula-
tory proposal," the Proposal for a Council Regulation (EEC) Laying
Down Community Provisions for the Authorization and Supervision of
Medicinal Products for Human and Veterinary Use and Establishing a
European Agency for the Evaluation of Medicinal Products, which
calls for centralization of marketing authorizations for biotechnology-
derived pharmaceuticals. 3 16 Such authorizations, the Commission now
believes, should be granted "only after a single scientific evaluation of
the highest possible quality of all the benefits and risks of technologi-
cally advanced medicinal products, . . . by a rapid procedure ensuring
close cooperation between the Commission and Member States. 37
A. A Single Scientific Evaluation of the Highest Possible Quality
The single scientific evaluation will be undertaken by a newly es-
tablished agency, entitled the European Agency for the Evaluation of
31. Id. (Seventh recital).
32. Id. (Ninth recital).
33. Id. arts. 1-2(2), at 38-39.
34. Id. art. 4(4), at 40.
35. Proposed Regulation, supra note 9, at 1 (Third recital); see also EC Proposes
Centralized Regulation of Pharmaceuticals, The Reuter Library Rep., Oct. 19, 1990,
available in LEXIS, Nexis Library ("In the majority of Community countries, the
authorisation systems are in crisis, paralysed by criticism from consumer groups and by
the number and complexity of cases to examine," while "[tihe absence of a credible
authorisation system valid throughout the Community is penalising its pharmaceutical
industry, including its exports." Id. (quoting a statement from the E.C. Commission)).
36. Proposed Regulation, supra note 9, at 1.
37. Id. at 2 (Eighth recital).
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Medicinal Products (Agency). 8 The Agency coordinates the scientific
review of the product for quality, safety and efficacy and presents re-
ports and summaries of its findings. 39
The CPMP, under the Agency's supervision, reviews documenta-
tion submitted by an expert for the applicant, certifying that the prod-
uct received specific testing for harmfulness and efficacy, as required by
Council Directive 75/318."1 Directive 75/318, as amended by Commis-
sion Directive 91/507, requires testing to be state-of-the-art and vali-
dated." ' Directive 91/507 also mandates documentation of chemical,
pharmaceutical, toxicological and clinical testing, and specifies the nec-
essary elements of those experiments.' 2
B. Risks
The Agency must examine and balance both consumer and envi-
ronmental risks created by a new product.' 3 Most. consumer risks are
studied and documented during quality, safety and efficacy testing,
pursuant to Directive 75/318, as amended."' Environmental risks, how-
ever, constitute a new element in the risk-benefit analysis for
38. Id. arts. 47-48,'at 12.
39. Id. art. 48(a)-(b), at 12.
40. Id. art. 6, at 3, citing Council Directive 75/319, art. 2, 1975 O.J. (L 147) at
14, which refers to Council Directive 75/318 on the Approximation of the Laws of
Member States Relating to Analytical, Pharmacotoxicological and Clinical Standards
and Protocols in Respect of the Testing of Proprietary Medicinal Products, 1975 O.J.
(L 147) 1, amended by Council Directive 89/341, 1989 O.J. (L 142) 11, modified by
Commission Directive 91/507, 1991 O.J. (L 270) 32.
41. Commission Directive 91/507, Annex, 1991 O.J. (L 270) 32, 36. ("All the
test procedures shall correspond to the state of scientific progress at the time and shall
be validated procedures; results of the validation studies shall be provided.").
42. Id. at 36-52.
43. Proposed Regulation, supra note 9, at 2 (Seventeenth recital) (describing the
.need for "intensive monitoring of adverse [clinical] reactions to those medicinal prod-
ucts through Community pharmacovigilance activities in order to ensure the rapid
withdrawal from the market of any medicinal product which presents an unacceptable
level of risk under normal conditions of use"),; Amended Proposed Regulation, supra
note 9, at 8 (Twentieth recital) (describing the need "to provide for an environmental
risk assessment of [medicinal products containing or consisting of genetically modified
organisms]").
44. Commission Directive 91/507, Annex, 1991 O.J. (L 270) at 34-52. Commis-
sion Directive 91/507 most recently amended Council Directive 75/318 by replacing
the Annex to Directive 75/318. The Annex outlines the types of tests and data that
must be submitted in an application for a marketing authorization. Under the new
Annex "Chemical, Pharmaceutical and Biological," "Toxicological and Pharmacologi-
cal" and "Clinical" tests are required. Commission Directive 91/507, Annex, 1991
O.J. (L 270) at 36-52.
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pharmaceuticals. Risks associated with intentional releases of geneti-
cally modified organisms into the environment (as in agricultural appli-
cations) have received increased attention in the E.C., culminating in
Council Directive 90/220. 45 The Amended Proposed Regulation has
adopted some of the provisions from Directive 90/220."0 Specifically,
the Amended Proposal requires each biotechnology pharmaceutical ap-
plication to include "a copy of the written consent, from the competent
authority, to the deliberate release of the genetically modified orga-
nisms for research and development purposes," and a "complete techni-
cal dossier supplying the information requested in Annexes II and III
of Directive 90/220 [characterizing the organisms, the release and the
environment] and the environmental risk assessment resulting from this
information."" 7
Though the Amended Proposed Regulation adopts some environ-
mental risk provisions from Directive 90/220, it does not adopt others.
Article 6(2) of the Amended Proposed Regulation, codifying environ-
mental requirements, states that Articles 11 through 18 of Directive
90/220 do not apply to the Amended Proposed Regulation. 8 Those
provisions pertain to the release of genetically modified organisms as
products. 49 Consequently, it appears that the environmental risk assess-
ment required under the Amended Proposed Regulation concerns only
releases into the environment pursuant to research and development,
not releases in the form of marketable goods. 50
There are two problems with this apparent import of the Amended
Proposed Regulation. First, it is impractical in application, because it is
difficult to conceive of the need for any deliberate release into the envi-
ronment of a pharmaceutical product during research and development.
In contrast with, for example, agricultural applications of biotechnol-
ogy products, medical applications of biotechnology products would not
involve deliberate environmental releases. Second, the Amended Pro-
45. Council Directive 90/220 on the Deliberate Release into the Environment of
Genetically Modified Organisms, 1990 O.J. (L 117) 15 (requiring, among other things,
a case-by-case environmental risk assessment prior to any release of genetically modi-
fied organisms into the environment. Id. (Ninth recital)).
46. The Amended Proposed Regulation adopts Article 2(1) & (2), Article 6(4),
and Annexes II and III from Council Directive 90/220. Amended Proposed Regula-
tion, supra note 9, art. 6(2) & (4), at 8-9.
47. Amended Proposed Regulation, supra note 9, art. 6(2), at 8-9.
48. Id. at 9.
49. Council Directive 90/220, arts. 11-18, 1990 O.J. (L 117) 18-20.
50. Note also that Article 6(4) from Directive 90/220 falls under Part B of the
Directive, entitled, "Deliberate release of GMOs into the environment for research and
development purposes or any other purpose than for placing in the market." Id. at 18.
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posed Regulation is unsound as a matter of policy in that it ignores
potential environmental releases from use of the product itself. Use of a
biotechnology-derived product by definition introduces an organism
into the human environment, which would almost certainly introduce it
into the greater environment. Inadvertent (but foreseeable) spillage of
drugs, discarding of partially used containers, or release of organisms
through human bodily fluids, such as blood or urine, would all intro-
duce organisms into the environment. Deliberate use should be seen as
synonymous with deliberate release, and should warrant an environ-
mental risk assessment. Unfortunately, the Amended Proposed Regula-
tion does not apply Directive 90/220 in such a fashion, and fails to
require an environmental assessment of risk from the use of biotechnol-
ogy-derived products.
C. Rapid Procedure
The Proposed Regulation ensures rapid processing of applications
by requiring quick turn-around at all stages of the procedure. For ex-
ample, the initial authorization opinion must be rendered by the Com-
mittee for Proprietary Medicinal Products (CPMP) (under supervision
of the European Agency for the Evaluation of Medicinal Products)
within 210 days after the CPMP receives an application.5 If, however,
the CPMP requests supplementation of the application, or if the appli-
cant prepares oral or written explanations at the CPMP's request, then
this time limit will be temporarily suspended.52 Once the initial opinion
is issued, the applicant has only fifteen days in which to notify the
Agency of an appeal.53 The CPMP, in turn, must make its final deter-
mination within sixty days of the appeal. 4 The supervisory Agency for-
wards the CPMP's final opinion with a report containing Committee
comments to the E.C. Commission, Member States and the applicant
within thirty days.55
Within thirty days of obtaining the CPMP opinion, the Commis-
sion prepares its draft Decision, which it transmits to the Member
States and the applicant.50 The Commission adopts the Decision within
thirty days unless "it has received a reasoned request from a Member
51. Amended Proposed Regulation, supra note 9, art. 6(4), at 9.
52. Proposed Regulation, supra note 9, art. 7(c), at 3-4.
53. Id. aft. 9(1), at 4.
54. Id.
55. Id. art. 9(2), at 4.
56. Amended Proposed Regulation, supra note 9, art. 10(1), at 9.
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State to reconsider." '57 If such a request is received, the Commission re-
assesses its decision, provided the request is based on scientific evidence
or Community law. 58 In the absence of any delays, authorizations may
be approved as quickly as 300 days after an application is submitted. It
is difficult to conceive of a more condensed timetable, given the com-
plex, multi-stage procedure.59
D. Close Cooperation
The Proposed Regulation provides for close cooperation between
the Commission and Member States through a number of means. As
indicated above, the various E.C. organs of the reviewing process com-
municate frequently with the applicant and Member States. The Pro-
posal also delineates cooperative networks between the Agency and the
Member States. For example, both the Agency and Member, States
must assist with the collection and review of pharmacovigilance infor-
mation.6" Member States are expected to notify the Agency of relevant
information about adverse reactions to authorized medicinal products,
and the Agency is responsible for collecting and evaluating this infor-
mation. 1 The Proposal also delegates some authority to Member
States. For example, it designates Member States as official "supervi-
sory authorities ' 62 to assure that manufacturers or importers are com-
plying with their authorization decisions, as provided by Directive 75/
319.113
The Proposed Regulation also includes provisions requiring the
Commission to respond to Member States' concerns. Thus if a Member
State informs the Commission that it believes a manufacturer or im-
porter is not fulfilling its Directive 75/319 obligations,64 the Commis-
57. Id. art. 10(2), at 10.
58. Id.
59. Marketing authorizations now take more than a year in the European coun-
tries, according to Bruce Merchant, chairperson of the Association of Biotechnology
Companies. See Biotech Approval Process Criticized by the Industry, CHEMICAL MAR-
KETING REP., Nov. 19, 1990, at 4, 4. Of course, approval in one country does not
guarantee approval in another, under the current national approval system in the E.C.
60. Proposed Regulation, supra note 9, arts. 19-25, at 6-7. Pharmacovigilance in-
volves "the collection and evaluation of information about adverse reactions to medici-
nal products." Id. art. 20, at 6.
61. Id.
62. Proposed Regulation, supra note 9, art. 16, at 5.
63. Id. See also id. art. 17(1), at 6, referencing Chapters IV and V of Council
Directive 75/319. These Chapters define the supervisory authorities' necessary qualifi-
cations and the extent of their duties.
64. Amended Proposed Regulation, supra note 9, art. 18(1), at 12.
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sion must review the matter and render a Decision.65 Similarly, where
a Member State makes a "reasoned request" 66 for an inspection of a
manufacturing site, the Commission may order such an investigation.6"
The Proposal even permits Member States to act on their own initia-
tive, for example, "where action is urgently necessary to protect public
health." 68 This element of cooperation should assure smoother approv-
als and better enforcement of the regulations.
III. INDUSTRY'S RESPONSE
A. Europe
E.C. industries have rated inconsistent technical regulations as the
most significant trade barrier within the Community. 9 Of all industries
adversely affected by technical barriers, European businesses rank the
pharmaceutical sector the fourth most hindered industry.70 The indus-
tries have also specifically blamed inconsistent technical standards for
creating expensive delays during certification and registration of
pharmaceuticals.7 1 Under the former national registration system, for
example, approval took up to three years in Italy and Spain, and up to
two years in Germany and the United Kingdom.7 1
Although E.C. businesses seem to believe that harmonization of
regulations for pharmaceutical authorizations is desirable, praise for
the Proposed Regulation is qualified. One British industry representa-
65. Proposed Regulation, supra note 9, art. 18(2)-(3), at 6.
66. Id. art. 17(2), at 6.
67. Id.
68. Amended Proposed Regulation, supra note 9, art. 18(4), at 12. Member
States may act without consulting the Commission in the following scenarios: (1)
where harm that could be caused would be so severe that the State cannot await a
Commission decision, (2) where it is likely that the suspected harm will occur during
Commission review, or (3) where the harm posed by the product outweighs the risk to
patients currently taking the medicinal product from removing the product from the
market, Id. art. 18(4)(l)-(3), at 12.
69. MICHAEL EMERSON ET AL., THE ECONOMICS OF 1992: THE E.C. COMMISSION'S
ASSESSMENT OF THE ECONOMIC EFFECTS OF COMPLETING THE INTERNAL MARKET 39
(1988). This conclusion was based on a 1987 study undertaken by G. Nerb, Director-
ate-General for Economic and Financial Affairs, Commission of the European Commu-
nities, entitled The Completion of the Internal Market: A Survey of European Indus-
try's Perception of the Likely Effects.
70. PAOLO CECCHINI ET AL., THE EUROPEAN CHALLENGE 1992: THE BENEFITS OF
A SINGLE MARKET 27, tbl. 4.1 (J. Robinson ed., 1988). This data was also gleaned
from the G. Nerb survey, mentioned supra note 69.
71. EMERSON, supra note 69, at 44.
72. Id. at 73.
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tive, for example, has remarked: "Intellectually we think they're going
down the right track, but the potential for bureaucratic nightmare is
high."' 73 Some European companies not only fear complex procedures,
but also voice concern about national biases among members on the
Committee for Proprietary Medicinal Products and the CPMP's advi-
sory Scientific Committee."' Although the Proposed Regulation re-
quires independent scientists to staff the CPMP, 75 European businesses
would like assurances that those experts are both highly competent and
impartial.76 The mood in Europe seems to be guarded optimism.
B. United States
The U.S. Chamber of Commerce describes the general E.C. har-
monization process as "potentially a double-edged sword for U.S. busi-
ness." 7 On the positive side, harmonization will mean that U.S. com-
panies need meet only one set of standards in order to market in all
E.C. member countries. However, those companies will operate at a
disadvantage if the U.S. is not included in the standard-setting process,
if U.S. testing and certifying entities are not recognized by central E.C.
agencies, or if the standards require expensive adjustments by Ameri-
can companies. 8
The U.S. National Association of Manufacturers (NAM) believes
that the "establishment of a new E.C.-wide standards process may af-
73. Tacey, supra note 16, at 39 (quoting Frances Charlesworth of the Association
of the British Pharmaceutical Industry).
74. See id. The Committee for Proprietary Medicinal Products (CPMP) is cur-
rently composed of representatives of national agencies. The proposed regulation theo-
retically will limit nationalistic tendencies by replacing these representatives with inde-
pendent scientific experts. See id.
In a recent meeting of the Council of Ministers, the Commission presented several
recommendations for facilitating neutral review by the Scientific Committee, which ad-
vises the CPMP. First, Scientific Committee members should represent the Member
States that appointed them. Second, Member States should not give those scientists
instructions that conflict with their committee obligations. Third, the Committee should
select rapporteurs to evaluate applications on behalf of the committee, not Member
States, and rapporteurs should coordinate the reviews. EC: Progress Towards Single
Market in Medicines at Council Meeting, Reuter Textline, Agence Europe, July 7,
1992, available in LEXIS, Nexis Library. These three recommendations would accom-
modate the dual need for Member State representation as well as independent scientific
reviews.
75. Proposed Regulation, supra note 9, art. 50(1), at 13.
76. See, e.g., Tacey, supra note 16, at 39.
77. INT'L Div., U.S. CHAMBER OF COMMERCE, supra note 10, at 45.
78. See id.
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fect more U.S. companies than any other EC-9279 issue."80 In addition,
NAM notes that, while the intent of such harmonization is not to open
E.C. markets to non-E.C. companies, non-E.C. companies stand to ben-
efit when they successfully receive clearance from one authority and
thus gain access to all E.C. markets.8 ' NAM concludes that "/i]n prin-
ciple, the adoption of common standards is widely seen by U.S. com-
panies in Europe as a major benefit.""2
Representatives from the National Bureau of Standards, however,
note that E.C.-wide standards may unintentionally restrict market ac-
cess for U.S. goods.83 The Bureau reiterates the warning of the Cham-
ber of Commerce that denying U.S. companies an early opportunity to
review and comment on E.C. proposals increases the likelihood that
later U.S. comments will not receive full consideration, 84 as well as the
possibility that the resulting standards may be unfavorable to them.85
Although the U.S. apparently had little input in formulating the
proposed E.C. regulation, federal regulators, industry representatives,
and scientists are encouraged by their recent discussions with E.C. reg-
ulators about harmonization of pharmaceutical registration proce-
dures.86  These parties attended an international conference on
pharmaceuticals, 87 which laid to rest some of the primary concerns of
79. "EC-92" refers to the anticipated completion of the European Common Mar-
ket and removal of all intra-E.C. trade barriers by 1992. In 1985 the E.C. Commission
drafted a-document entitled, Completing the Internal Market: White Paper from the
Commission to the European Council (Luxembourg, 1985), which sets forth the unifi-
cation plan. See STEPHEN COONEY, NAT'L Assoc. OF MANUFACTURERS, EC-92 AND
U.S. INDUSTRY 9-12 (1989).
80. COONEY, supra note 79, at 15.
81. Id.
82. Id. at 17.
83. Patrick W. Cooke & Donald R. Mackay, The New EC Approach to Harmo-
nization of Standards and Certification, Bus. AM., Aug. 1, 1988, reprinted in COONEY,
supra note 79, at 49 app. The U.S. Chamber of Commerce notes that the E.C. could
also deliberately adopt standards that would be incompatible with U.S. goods, in order
to attain a competitive advantage. INT'L Div., U.S. CHAMBER OF COMMERCE, supra
note 10, at 47.
84. Cooke & Mackay, supra note 83, in COONEY, supra note 79, At 49.
85. Id.
86. See THE FIRST INTERNATIONAL CONFERENCE ON HARMONISATION, PRESS RE-
LEASE (Nov. 8, 1991), reprinted in INTERNATIONAL CONFERENCE ON HARMONISATION
OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN
USE, at 5 (1991).
87. Over 1200 people attended the conference. Participants included the Commis-
sion of the European Communities, the U.S. Food and Drug Administration, the Japa-
nese Ministry of Health and Welfare, the International Federation of Pharmaceutical
Manufacturers Associations, the European Federation of Pharmaceutical Industry As-
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the Chamber of Commerce. For example, the participating regulatory
agencies agreed to accept certain data evaluations from each other in
order to promote efficiency and to control costs. 88 The consensus of this
meeting and of numerous businesspersons seems to be that harmoniza-
tion will be beneficial in the long run, if somewhat painful in the short
term.
IV. U.S. REGULATIONS AND POLICIES TOWARDS APPROVAL OF
BIOTECHNOLOGY PHARMACEUTICALS
In contrast to the proposed E.C. regulatory framework, the federal
regulatory landscape is a bit more haphazard. Federal policies concern-
ing approval of drugs for the U.S. market are neither simple nor fixed.
Moreover, U.S. laws do not apply readily to biotechnology products be-
cause the laws have not been altered to reflect the peculiarities of those
goods.89 In contrast, the E.C.'s proposed regulation directly addresses
public health concerns about biotechnology products. Rather than mod-
ifying its regulations, the F.D.A. has instead adopted various policies
pertaining to biotechnology drug approvals.90 For example, the agency
sociations, the U.S. Pharmaceutical Manufacturers Association and the Japanese Phar-
maceutical Manufacturers Association. Id.
88. See id. The point of this principle is to avoid unnecessary duplication of test-
ing to comply with the varying standards of different regulatory agencies.
89. 51 Fed. Reg. 23,309, 23,310 (1986). The F.D.A. concedes "there are no statu-
tory provisions or regulations that address biotechnology specifically .... " Id. None-
theless, the agency maintains that existing laws and rules suffice and that agency per-
sonnel can capably administer them. ("[T]he laws and regulations under which the
agency approves products place the burden of proof of safety as well as effectiveness on
the manufacturer. The agency possesses extensive expertise with these regulatory
mechanisms and applies them to the products of biotechnological processes.").
90. The F.D.A. has described these documents as "guidance to current or prospec-
tive manufacturers of drugs and biological products . . . describing points that manu-
facturers might wish to consider in the production and testing of products." 51 Fed.
Reg. at 23,311 (1986). Although these documents instruct the applicants, because they
are not binding they do not promote regulatory consistency. F.D.A. comments in a
recent Federal Register notice suggest that the approval process is becoming even more
ambiguous:
The supplement (to this points to consider document] has been developed to
revise and update information in a previously issued points to consider (PTC)
document in order to improve the document's usefulness; it is neither a regu-
lation nor a guideline, but represents the current thinking of the [F.D.A.]
Center for Biologics Evaluation and Research (CBER).
. . . A manufacturer may choose to use alternative procedures even though
they are not described in the PTC and this PTC supplement. A manufacturer
who wishes to use other procedures is encouraged to discuss the matter with
the agency.
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recommends certain testing procedures in periodic "Points to Consider"
documents,"' and has announced its intent to conduct case-by-case
review. 92
A. A Single Scientific Evaluation of the Highest Possible Quality
The F.D.A. also implements the four broad principles of the E.C.
proposal somewhat differently. As the sole federal agency empowered
to approve drugs, it does, however, conduct a single scientific evalua-
tion. Although the F.D.A. oversees all review, different types of bio-
technology materials are approved by separate divisions of the agency.
"Biological products," 93 for example, are licensed for marketing by the
Center for Biologics Evaluation and Research.94 "New drugs," 95 mean-
Notice, 57 Fed. Reg. 33,201, 33,202 (1992) (emphasis added).
91. 51 Fed. Reg. at 23,311 (1986).
92. Id.
93. "Biological product," or biologic, means "any virus, therapeutic serum, toxin,
antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analo-
gous product, or arsphenamine or its derivatives (or any other trivalent organic arsenic
compound)." Public Health Service Act, 42 U.S.C. § 262(a) (1988).
94. The Center for Biologics Evaluation and Research (CBER) licenses both bio-
logic products and establishments that manufacture those products. 21 C.F.R. §
601.4(a) (1992). Because the products are organic and may contain elusive contami-
nants such as viruses or natural toxins, biologics review is highly complex. Conse-
quently, the CBER reviews the manufacturing process carefully for flaws. Telephone
Interview with Steve Falter, Director of the Division of Regulations and Bioresearch
Monitoring, Center for Biologics Evaluation and Research, Food and Drug Adminis-
tration (Oct. 16, 1992) [hereinafter Telephone Interview with Falter].
95. "New drug" is defined as a drug "not generally recognized, among experts
qualified by scientific training and experience to evaluate the safety and effectiveness of
drugs, as safe and effective." Federal Food, Drug and Cosmetic Act, 21 U.S.C. §
321(p)(1) (1988).
"Drugs" are defined as articles intended for diagnosing, curing, mitigating, treat-
ing, preventing disease, or affecting the structure or function of the body. 21 U.S.C. §
321(g)(l) (1988).
Manufacturers of drugs that are not "new," but generally recognized as safe and
effective (GRASE), need not submit new drug applications. Arguably, biotechnology-
derived versions of GRASE drugs (previously approved and manufactured using con-
ventional processes) should be exempt from the new drug approval process. Histori-
cally, however, the F.D.A. has considered all biotechnology-derived drugs as "new."
See Points to Consider in the Production and Testing of New Drugs and Biologicals
Produced by Recombinant DNA Technology, letter from Elaine C. Esber, M.D., Di-
rector, Office of Biologics Research and Review, Food and Drug Administration, to
Manufacturers of Recombinant DNA Products and other Interested Parties at 3 (Apr.
10, 1985) [hereinafter Points to Consider, letter from Esber] ("New license applica-
tions or new drug applications are required before marketing products made with re-
combinant DNA technology, even if the active ingredient in the product is thought to
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while, receive marketing approval from the Center for Drug Evaluation
and Research.96 Despite this branched approach, the reviews of bio-
logics and new drugs are "functionally very similar. ' 97 The agency has
jurisdiction over both forms of pharmaceuticals and thus its review re-
mains centralized.
Arguably, however, the F.D.A. procedure fails to ensure review of
the highest possible quality. The reason for this appears to be the ab-
sence of mandated research and testing standards. For example, the
F.D.A. recommends that biotechnology companies seeking federal ap-
proval follow the rigorous National Institutes of Health Guidelines for
be identical in molecular structure to a naturally occurring substance or a previously
approved product produced in an established manner." Points to Consider documents
can be obtained from the F.D.A. by writing to the Congressional and Public Affairs
Staff at the agency.) In a fairly recent policy statement, F.D.A. repeated its "general
principle, [that] new marketing applications will be required for most products manu-
factured using new biotechnology." 51 Fed. Reg. 23,309 (1986). Importantly, however,
the agency qualified this maxim: "[E]ach case will be examined separately to deter-
mine the appropriate information to be submitted. In some instances new applications
may not be required." Id.
96. In contrast to the Center for Biologics Evaluation and Research, the Center
for Drug Evaluation and Research approves only products, not establishments. In this
sense the application for new drugs requires less data than one for biologicals. See
Robert A. Swanson, Culturing a Biotech Company in a Regulatory Medium, in DRUG
BIOTECHNOLOGY REGULATION: SCIENTIFIC BASIS AND PRACTICES 382, 385 (Yuan-
yuan H. Chiu & John L. Gueriguian eds., 1991).
However, unlike biologic licensee applicants, new drug applicants must undertake
multiple, carefully controlled human studies that demonstrate the drug's effectiveness.
See Weinberger v. Hynson, Westcott & Dunning, Inc., 412 U.S. 609, 617-18 (1973)
(concluding that a showing of efficacy for a new drug includes evidence of adequate
and well-controlled clinical studies). Although the Supreme Court has found that the
Federal Food, Drug and Cosmetic Act requires these sorts of human trials, it has never
found them necessary under the Public Health Service Act, governing biologicals. Tele-
phone Interview with Falter, supra note 94.
As one might expect, because the requirements for biologics and new drugs vary
slightly, pharmaceutical companies might prefer one label over the other. For example,
an applicant would be spared scrutiny of its manufacturing process if the product re-
ceived the "new drug" label. (Note that the Federal Food, Drug and Cosmetic Act
authorizes the F.D.A. to enter and inspect any manufacturing establishments. 21
U.S.C. § 374(a) (1988). These inspections are not tied to the approval process, how-
ever.) On the other hand, an applicant would be relieved from conducting extensive
drug efficacy trials in humans if the product were deemed a "biological product." The
F.D.A. determines whether a product falls into one category or the other. Understanda-
bly, characterization is often difficult. Many biotechnology products are reviewed as
biologics.
97. Telephone Interview with Falter, supra note 94.
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Research Involving Recombinant DNA Molecules,"8 but goes no fur-
ther.99 The N.I.H. Guidelines, themselves, technically apply only to
federally funded projects.' In addition, because the agency publishes
advisory "Points to Consider" documents for biotechnology products,
rather than issuing legally binding regulations, it cannot guarantee con-
sistency among biotechnology applicants.'
Although these policies provide the flexibility necessary to respond
to rapidly changing technology, they also expose the agency to outside
pressures. For example, the Executive Branch has taken a keen interest
in promoting biotechnology, expressing its intent to "oppose any efforts
to create or modify existing regulatory structures for biotechnology
through legislation."'0 2 A recent announcement from the administra-
tion's Office of Science and Technology Policy (OSTP) reflects this
anti-regulatory agenda.'0 3 The OSTP declared that, "within the scope
of discretion afforded by statute [oversight] should not turn on the fact
that an organism has been modified or modified by a particular process
or technique, because such fact is not alone a sufficient indication of
risk."'0 4
This policy runs counter to current F.D.A. practice, at least with
respect to biotechnology drugs. The agency treats these drugs as
"new,"'10 5 which means applicants must submit a lengthy application
and reams of scientific data. It is soundly within agency discretion to
98. National Institutes of Health: Guidelines for Research Involving Recombinant
DNA Molecules, 51 Fed. Reg. 16,958 (1986). The first version of this document was
published in 1976. 41 Fed. Reg. 27,906 (1976). Among other things, the Guidelines
restrict certain types of experiments, define levels of physical and biological contain-
ment, establish containment levels according to level of risks, and define the roles of the
various participants. See Gregory A. Jaffe, Inadequacies in the Federal Regulation of
Biotechnology, I1 HARV. ENVTL. L. REV. 491, 498 (1987).
99. See Points to Consider, letter from Esber, supra note 95, at 3. The Points to
Consider document mentions that there may be other applicable guidelines for import-
ers, e.g., from the World Health Organization. Id.
100. 51 Fed. Reg. 16,958, 16,965 (1986). Because, according to one estimate,
more than 90% of all recombinant DNA research is privately funded, the N.I.H.
Guidelines may have little impact on most research, particularly commercial research.
See Jaffe, supra note 98, at 534.
101. See supra note 90.
102. THE PRESIDENT'S COUNCIL ON COMPETITIVENESS, supra note 24, at 14.
103. Office of Science and Technology Policy: Exercise of Federal Oversight
Within Scope of Statutory Authority: Planned Introductions of Biotechnology Products
into the Environment, 57 Fed. Reg. 6753 (1992).
104. Id. at 6756.
105. See supra note 95.
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treat biotechnology-derived drugs as either "new" or GRASE, °6 where
the product had been previously approved using conventional tech-
niques. Consequently, this OSTP policy may radically alter F.D.A. re-
view practices.
B, Risks
Similar to the CPMP, the F.D.A. does conduct a risk analysis.
Consumer risks are subsumed in the general review, but environmental
risks are evaluated somewhat differently. The National Environmental
Policy Act (NEPA),'10 7 which requires an environmental impact assess-
ment for all "major Federal actions significantly affecting the quality
of the human environment,"10 applies to all premarketing approvals by
the agency.10 9 Although the F.D.A. believes that most new products
only require submission of a brief environmental assessment,110 a
lengthy environmental impact statement is necessary for products that
may cause significant environmental impacts.1 Because risk assess-
ments under the Federal Food, Drug and Cosmetic Act are not limited
to research and development risks, as under the proposed E.C. regula-
tions, review of environmental risks may be more thorough in the
United States than in the European Community.
C. Rapid Procedure
Like its European counterparts, the F.D.A. has been unable to
achieve rapid procedure. Agency approval has been very slow, largely
due to understaffing. 2 According to the Pharmaceutical Manufactur-
106. Weinberger v. Hynson, Westcott & Dunning, Inc., 412 U.S. 609, 627
(1973).
107. National Environmental Policy Act, 42 U.S.C. §§ 4321-4364 (1988).
108. Id. § 4332(C).
109. 51 Fed. Reg. 23,309, 23,313 (1986). See also 21 C.F.R. § 25.22(a)(14) &
(16) (1992) (requiring submission of an environmental assessment when seeking ap-
proval for new drugs and licensing of biological products).
110. 51 Fed. Reg. 23,313 (1986) ("For new products or major new uses for ex-
isting products, these INEPA-implementing] procedures ordinarily require the prepara-
tion of an environmental assessment.").
111. Id. ("An environmental impact statement is required if the manufacture, use,
or disposal of the product is anticipated to cause significant environmental impacts.").
112. See, e.g., U.S. Says It Will Speed, supra note 21, at D2. Approval in the
U.S. averages 32 months for new drugs, though approval of biotechnology-derived new
drugs generally requires only half of the time. OFFICE OF TECHNOLOGY ASSESSMENT,
supra note 24, at 90. The Office of Technology Assessment concludes that drug ap-
proval is often slower in the United States than in the rest of the world. Id.
See also Biotech Approval Process Criticized by the Industry, supra note 59, at 4
REGULATION OF BIOTECHNOLOGY
ers Association, for example, only two biotechnology products were ap-
proved last year, while twenty-one awaited approval and over 130 were
undergoing review.11 Overall, the agency approved thirty new drugs
and eight biologics in 1991 (including both biotechnology-derived and
conventional products).1" ' To improve its sluggish pace, the agency re-
cently announced plans to hire fifty new scientists to review biotechnol-
ogy applications. 1 5 One senior official from the agency indicated the
F.D.A.'s intention "not. [to] be obstructionist" and to "keep our stan-
dards but .. . [to] make things move.""' 6
Congress passed a unique piece of legislation in the waning hours
of the 102d Congress in an attempt to fund and expedite F.D.A. re-
view." The "Prescription Drug User Fee Act of 1992" aims to cut
review time in half. 1 8 It will raise $300,000,000 by the close of 1997,
allowing the agency to hire 600 additional examiners. 19 Under this
Act, pharmaceutical companies will pay the F.D.A. $100,000 per drug
(or biologic) application, $50,000 per year and at least $6,000 per drug
on the market. In five years those fees will increase to $233,000,
$138,000 and $14,000, respectively.' 20 Congress secured industry's sup-
port because approval delays cost companies more than user fees: every
month approval is delayed translates into $10,000,000 of lost profits.''
Moreover, Congress ensured the backing of pharmaceutical firms by
(citing ABC chairperson Bruce Merchant's estimate of 34 months for biotechnology-
derived biologic licensing approvals); FDA Approves 30 Drugs in 1991 in Average of
30.3 Months, WORLD PHARMACEUTICAL STANDARDS REV., Mar. 1992, at 9, 9 (citing
the Pharmaceutical Manufacturers Association's estimate of 30.3 months for new drug
approvals) [hereinafter FDA Approves]; Drugs, User Fee System is Essential for FDA
to Keep Pace with NDAs, Kessler Says, DAILY REP. for EXECUTIVES (BNA) No. 155,
at A9, A9 (Aug. 11, 1992) (citing F.D.A. Commissioner Kessler's recent estimate that
approval of new drugs takes 20 months, while approval of breakthrough drugs takes 12
months). "Breakthrough" drugs treat serious illnesses for which there are no cures,
such as AIDS, cancer or Alzheimer's disease. See Alex Barnum, FDA Speeding up
Drug Testing,- Outside Contractors Will Help Review Applications in Some Cases,
THE S.F. CHRONICLE, Apr. 10, 1992, at A9.
113. See FDA Approves, supra note 112, at 9.
114. See id.
115. See, e.g., U.S. Says It Will Speed, supra note 21, at D2.
116. Id.
117. Prescription Drug User Fee Act of 1992, H.R. 6181, 102d Cong., 2d Sess.
(1992).
118. Philip J. Hilts, Senate Passes Bill to Charge Makers for Drug Approval,
N.Y. TIMES, Oct. 8, 1992, at Al.
119. Id.
120. Id. at B25.
121. Id. at Al.
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convincing them that the fees would benefit the review process
directly. 22
D. Close Cooperation
Regulation in the U.S. does not require the cooperation of sover-
eign Member States, as .in the European Community. Although indi-
vidual U.S. states may regulate biotechnology,' 23 regulation in the U.S.
is almost entirely federal. Thus, harmonization of state laws is essen-
tially a non-issue. Close coordination between the agency and appli-
cants, on the other hand, raises certain conflict-of-interest issues.
Arguably, active dialogue between the applicant and the F.D.A.
clarifies and hastens the approval process. Ostensibly towards this end,
the agency has expressed its intent to be "user-friendly." "2 However,
the F.D.A. has been criticized for its ties to industry, and has been
labeled the "Chamber of Commerce" of biotechnology. 25 Importantly,
it should not be forgotten that F.D.A.'s central legal obligation is to
protect the public from dangerous foods, drugs, and cosmetics. 126 The
appropriate amount of interaction between the F.D.A. and industry is
clearly debatable; the recent federal policy, however, has been to
strengthen and expand government and industry collaborations.2 7 As
122. Id. at B25.
123. State and local regulation is rare, however. For a discussion of some state
and local regulations, see Diane Hoffman, The Biotechnology Revolution and its Regu-
latory Evolution, 38 DRAKE L. REV. 471, 537-39 (1988-1989). Note, for example, that
Maryland enacted a statute in 1977, requiring all researchers to comply with the
N.I.H. Guidelines. This Maryland statute expired in 1982. Recombinant DNA Re-
search, ch. 847, 1977 Md. Laws 3305.
124. BUREAU OF NATIONAL AFFAIRS, U.S. BIOTECHNOLOGY: A LEGISLATIVE AND
REGULATORY ROADMAP 21 (1989) (quoting former F.D.A. Commissioner Frank
Young) [hereinafter U.S. BIOTECHNOLOGY].
125. Id. at 27. Andrew Kimbrell, policy director for Jerry Rifkin's public interest
group, the Foundation on Economic Trends, is credited with this characterization. He
claims that the F.D.A. acts "as a promoter [of biotechnology] rather than a regulatory
agency." Id. (alteration in original).
126. See 62 Cases, More or Less, Each Containing Six Jars of Jam v. United
States, 340 U.S. 593 (1950), which held:
The purposes of this [FFDCA] legislation, we have said, "touch phases of the
lives and health of people which, in the circumstances of modern industrial-
ism, are largely beyond self-protection. Regard for these purposes should in-
fuse construction of the legislation if it is to be treated as a working instru-
ment of government and not merely as a collection of English words."
Id. at 596 (quoting United States v. Dotterweich, 320 U.S. 277, 280 (1943)).
127. Government collaboration, or assistance that tends to strengthen ties between
the public and private sector, includes research funding and tax reform, as well as
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long as policymakers believe that public and private sector cooperation
improve the U.S.' competitive edge, we can probably expect to see this
trend continue.
In summary, F.D.A. review is less standardized and less rule-
bound than the proposed E.C. process. As indicated above, the recent
tendency has been to relax those malleable F.D.A. policies further. The
trend towards deregulation of biotechnology products seems clear in
this country. Consequently, the reverse trend in the E.C. may have a
striking effect.
V. THE E.C. REGULATION AND ITS EFFECT ON THE
BIOTECHNOLOGY INDUSTRY
The importance of the biotechnology industry to the U.S. economy
cannot be overemphasized." 8 It remains one of the few industries in
industry and government research collaborations.
The U.S. is clearly committed to providing financial assistance for biotechnology
research. See THE PRESIDENT'S COUNCIL ON COMPETITIVENESS, supra note 24, at 6.
According to the President's Council, the U.S. invested $3.5 billion in biotechnology-
related research in fiscal year 1990. Id. The Office of Technology Assessment estimates
that the government funds over half of all biotechnology-related research in the United
States. OFFICE OF TECHNOLOGY ASSESSMENT, supra note 24, at 163.
Tax credits for biotechnology companies may be particularly helpful to spur indus-
try growth, because biotechnology requires an inordinate amount of investment in re-
search and development. See OFFICE OF TECHNOLOGY ASSESSMENT, supra note 24, at
64. American biotechnology companies benefit from several such tax credits. See id. at
64-66 for a discussion of available U.S. tax breaks.
Although on a small scale only, the government has formed several collaborative
arrangements with industry. For example, the F.D.A. plans to establish a National
Center for Toxicological Research, in Arkansas, and to rent a portion of its space and
equipment to start-up biotechnology firms short on capital. See U.S. BIOTECHNOLOGY,
supra note 124, at 26.
128. Biotechnology is considered an industry of great importance for the present
as well as the future. Its importance has been equated with the computer industry. See
JOHN NAISBITT & PATRICIA ABURDENE, MEGATRENDS 2000, at 260 (1990). In addi-
tion, because the U.S. leads in research and commercialization of biotechnology, Amer-
ican industry proponents see the industry as presenting a golden opportunity for the
U.S. economy.
Growth in the U.S. has been rapid. In the last four years, development of biotech-
nology-derived pharmaceuticals has increased by 60% in the United States, according
to a survey by the Pharmaceutical Manufacturers Association. See USA: Biotech
Drugs; Research in the US and Europe, Reuter Textline, Chemical Business News
Base, May 29, 1992, available in LEXIS, Nexis Library. Moreover, since 1983, the
number of jobs has increased 10-fold, from 5,000 to 50,000. Biotechnology Research to
Receive Increased Funding, National Commitment, According to U.S. Report, WORLD
PHARMACEUTICAL STANDARDS REV., Mar. 1990, at 13, 13 (citing comments from For-
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which the U.S. is the most technically advanced. The U.S. also boasts
close ties between industry and academia, 1 9 which should ensure con-
tinued development in the future. If these strengths can be exploited
commercially, it is possible that the industry will become "the automo-
bile industry of the future." ' It is easy to understand why regulators
have begun to succumb to economic pressures.
Success in this industry requires not only a solid research base,
however, but the ability to reach global markets. International market-
ing has already begun: over one third of all drugs sold in the Commu-
nity are imported, mostly from the U.S. and Switzerland.3 ' Moreover,
the European market is crucial to American biotechnology pharmaceu-
tical companies; biotechnology products are still extremely expensive to
produce, due to astronomical research and development costs.' 32 Broad-
based marketing is clearly important for companies seeking to recoup
their costs.
Marketing in the E.C. is also appealing to U.S. corporations be-
cause entry into one country will mean immediate entry into eleven
others. Because marketing in Europe is so desirable, it appears that
U.S. biotechnology pharmaceutical companies will feel compelled to
comply with the proposed E.C. regulation. The paradox of this other-
wise burdensome regulation is that compliance with it will enhance the
ability of U.S. companies to compete. The incentive to comply will be
great. Although U.S. regulators are showing neither the conviction nor
the interest in imposing strict public health and quality standards, the
E.C. has, and for once, both the public and industry stand to gain.
Colleen K. Ottoson
rest Anthony, president of the Association of Biotechnology Companies, during a Janu-
ary 29, 1992 press conference). The industry has not even experienced a decline during
the current economic recession, with sales in 1991 approaching $4 billion. Id. Finally,
the U.S. trade balance is also healthy, with exports exceeding imports. Id.
129. See, e.g., ORGANIZATION FOR ECONOMIC CO-OPERATION AND DEVELOP-
MENT, BIOTECHNOLOGY AND THE CHANGING ROLE OF GOVERNMENT 39 (1988).
130. Biotechnology: Draft of Long-Awaited 'Scope' Document Calls for Risk-
Based Regulatory Approach, DAILY REP. FOR EXECUTIVES (BNA) No. 36, at A-4
(Feb. 24, 1992) (quoting William Small, Executive Director of the Association of Bio-
technology Companies).
131. See, e.g., EMERSON, supra note 69, at 71.
132. See, e.g., BUREAU OF NATIONAL AFFAIRS, THE BIOTECH BUSINESS: FINAN-
CIAL OUTLOOK AND ANALYSIS 7-23 (1989). For example, research and development
expenses can reach $45,000 per employee. Id. at 18.
